SOUTH SAN FRANCISCO, CA--(Marketwire - June 09, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that interim results from an ongoing Phase IIa clinical trial in stable heart failure patients evaluating CK-1827452, a novel cardiac myosin activator being developed for the potential treatment of patients with either acutely decompensated or chronic heart failure, are scheduled to be presented as part of the Late Breaking Trials Session at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology, to be held June 14-17, 2008 in Milan, Italy.
